News Novartis sets sights on new oral MS drug after phase 3 wins Novartis' oral BTK inhibitor remibrutinib has shown efficacy in a pair of phase 3 trials in multiple sclerosis, boosting its blockbuster credentials.
News Novartis halts CAR-T trials after patient deaths Novartis stops eight trials of CAR-T rap-cel in autoimmune diseases after three deaths, with BMS also halting studies of zola-cel as a precaution.
News ESC26: Can Arrowhead pierce Ionis' triglyceride armour? Arrowhead Pharma is squaring up to rival Ionis in the severe hypertriglyceridaemia (sHTG) market, drawing on phase 3 data at ESC 2026.
News ESC26: AZ's relaxin agonist shows promise in heart failure An oral relaxin agonist developed by AstraZeneca, codenamed AZD5462, has been shown to improve cardiac function in patients with heart failure.
News ESC26: Cytokinetics' big data reveal for Myqorzo impresses Cytokinetics has revealed highly anticipated data from the ACACIA-HCM study of Myqorzo in non-obstructive hypertrophic cardiomyopathy at ESC 2026.
R&D When metrics measure more than they improve The question to ask is not, "Are we measuring site performance?" but, "Are the metrics we collect providing actionable insights early enough?"
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.